Evaluation of Anticancer Efficacy of D-α-Tocopheryl Polyethylene-Glycol Succinate and Soluplus ® Mixed Micelles Loaded with Olaparib and Rapamycin Against Ovarian Cancer

• Published in: International journal of nanomedicine 2024-01, Vol.19, p.7871-7893
• Main Authors: Shin, Yu Been, Choi, Ju-Yeon, Yoon, Moon Sup, Yoo, Myeong Kyun, Shin, Dae Hwan, Lee, Jeong-Won
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; antitumor efficacy; Cell Line, Tumor; Cell Survival - drug effects; combination therapy; Drug Carriers - chemistry; Female; Humans; iv formula; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; mixed micelle; nanoformulation; Original Research; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Phthalazines - administration & dosage; Phthalazines - chemistry; Phthalazines - pharmacokinetics; Phthalazines - pharmacology; Piperazines - chemistry; Piperazines - pharmacology; Polyethylene Glycols - chemistry; Polyvinyls - chemistry; Polyvinyls - pharmacology; Sirolimus - administration & dosage; Sirolimus - chemistry; Sirolimus - pharmacokinetics; Sirolimus - pharmacology; Vitamin E - chemistry; Vitamin E - pharmacology; Xenograft Model Antitumor Assays
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S468935

Ovarian cancer has the highest mortality rate and lowest survival rate among female reproductive system malignancies. There are treatment options of surgery and chemotherapy, but both are limited. In this study, we developed and evaluated micelles composed of D-α-tocopheryl polyethylene-glycol (PEG) 1000 succinate (TPGS) and Soluplus (SOL) loaded with olaparib (OLA), a poly(ADP-ribose)polymerase (PARP) inhibitor, and rapamycin (RAPA), a mammalian target of rapamycin (mTOR) inhibitor in ovarian cancer. We prepared micelles containing different molar ratios of OLA and RAPA embedded in different weight ratios of TPGS and SOL (OLA/RAPA-TPGS/SOL) were prepared and physicochemical characterized. Furthermore, we performed in vitro cytotoxicity experiments of OLA, RAPA, and OLA/RAPA-TPGS/SOL. In vivo toxicity and antitumor efficacy assays were also performed to assess the efficacy of the mixed micellar system. OLA/RAPA-TPGS/SOL containing a 4:1 TPGS:SOL weight ratio and a 2:3 OLA:RAPA molar ratio showed synergistic effects and were optimized. The drug encapsulation efficiency of this formulation was >65%, and the physicochemical properties were sustained for 180 days. Moreover, the formulation had a high cell uptake rate and significantly inhibited cell migration (** < 0.01). In the in vivo toxicity test, no toxicity was observed, with the exception of the high dose group. Furthermore, OLA/RAPA-TPGS/SOL markedly inhibited tumor spheroid and tumor growth in vivo. Compared to the control, OLA/RAPA-TPGS/SOL showed significant tumor inhibition. These findings lay a foundation for the use of TPGS/SOL mixed micelles loaded with OLA and RAPA in the treatment of ovarian cancer.